• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Invasive Candidiasis
    • Invasive Aspergillosis
    • Refractory Invasive Fungal Infections
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data

Press Releases

Investors

Investors

  • Overview
  • News Releases
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Proxy Statements
    • Quarterly Results
    • Key Ratios
  • Stock Data
    • Quote
    • Historical Data
    • Investor Calculator
    • Analyst Coverage
    • Ownership Profile
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News Releases

  • Press Releases
  • Email Alerts

SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

Jan 30, 2019

SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors

Jan 22, 2019

SCYNEXIS Provides Year-end Update and Outlines Plans for 2019

Jan 3, 2019

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Nov 20, 2018

SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

Nov 13, 2018

SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp

Oct 23, 2018

SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

Oct 15, 2018

SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week

Oct 1, 2018

SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018

Sep 26, 2018

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Sep 25, 2018
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...12

1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
View Google Map

© 2019 SCYNEXIS, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Contact Us